Search Results for "lubiprostone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for lubiprostone. Results 11 to 17 of 17 total matches.
See also: Amitiza
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
▶ Detected in minimal amounts in breast milk2
Lubiprostone (Amitiza) ▶ Avoid use
▶ No adequate studies ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, a secretagogue
such as lubiprostone (Amitiza, and generics),
linaclotide (Linzess), or plecanatide (Trulance ...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
(Trulance), and lubiprostone (Amitiza)
and the prokinetic drug prucalopride (Motegrity),
may be considered ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
drug such as linaclotide (Linzess),
plecanatide (Trulance), or lubiprostone (Amitiza ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
Lubiprostone – Amitiza
(Takeda/Sucampo)
8, 24 mcg caps 24 mcg PO bid with food and
water
Moderate hepatic ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
agonist that increases intraluminal
fluid and accelerates intestinal transit, and lubiprostone
(Amitiza ...
Rifaximin (Xifaxan – Salix), a minimally absorbed
oral antibiotic approved previously to treat travelers'
diarrhea and to reduce the risk of recurrent hepatic
encephalopathy, has now been approved by the FDA
for treatment of irritable bowel syndrome with diarrhea
(IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid
receptor agonist, was also recently approved for IBS-D
and will be reviewed in a future issue.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
.
They appear to be similar in efficacy and safety, but
no direct comparisons are available.13-15 Lubiprostone ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.